Results 171 to 180 of about 48,847 (353)

Atrial overdrive pacing in drug-refractory postinfarction electrical storm case report. [PDF]

Medicine (Baltimore)
Xu XY, He RX, Wang HJ, Liu P, Ma GL, Ji LN, Qi BY, Liu XP.   +7 more
europepmc   +1 more source

Low ICU Admission and Excellent Outcomes in MIS‐C: A Swedish Study From an Open Society

Acta Paediatrica, Volume 115, Issue 2, Page 335-344, February 2026.
ABSTRACT Aim During the COVID‐19 pandemic, Sweden chose a more open public health approach. A general concern was that this approach would affect the population negatively. We describe the Swedish national MIS‐C cohort and risk factors for severe disease defined as admission to the intensive care unit and cardiogenic shock.
Petra Król, Maria Altman, Stefan Berg, Lillemor Berntson, Petter Brodin, Anders Fasth, Robin Kahn, Jenny Lingman Framme, Maria Mossberg, Charlotta Nordenhäll, Karin Palmblad, André Rudolph, Eva Säve‐Söderbergh, AnnaCarin Horne   +13 more
wiley   +1 more source

Preventive Effect of Shenfu Injection on Arrhythmia After Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction: A Prospective Randomized Controlled Trial. [PDF]

Cardiovasc Ther
Qiu X, Wang Y, Ke J, Wang M, Zeng H, Zhu H, Gu J.   +6 more
europepmc   +1 more source

Intravesical oxybutynin for bladder capacity in children with spina bifida: the ‘Place de l’OXybutynine Intravésicale chez le Patient Enfant Neurologique’ (POXIPEN) trial protocol

BJU International, Volume 137, Issue 2, Page 390-398, February 2026.
Background Neurogenic bladder is defined as a dysfunction of the bladder resulting from damage to the central or peripheral nervous systems. Its treatment is based on a progressive therapeutic escalation, rapidly involving invasive therapeutic procedures such as repeated intradetrusor injections and surgery.
Marie Buzzi, Jonathan Epstein, Zahi Hatem, Nadine Juge, Charles Mazeaud, Jean‐Louis Lemelle, Nicolas Berte   +6 more
wiley   +1 more source

Impact of GLP-1 Receptor Agonist Therapy on Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients: A Real-World Data Analysis. [PDF]

Circ Arrhythm Electrophysiol
Venier S, Defaye P, Lochon L, Benali R, Bisson A, Carabelli A, Diouf Y, Jacon P, Fauchier L.   +8 more
europepmc   +1 more source

Sodium glucose co‐transporter 2 inhibitors versus dipeptidyl peptidase‐4 inhibitors and the risk of ventricular arrhythmia among patients with type 2 diabetes: A population‐based cohort study

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 935-945, February 2026.
Abstract Aims To determine whether sodium glucose co‐transporter 2 inhibitors (SGLT2i) use, compared with dipeptidyl peptidase‐4 inhibitors (DPP4i) use, is associated with the risk of ventricular arrhythmias (VA) among patients with type 2 diabetes. Materials and Methods We conducted a population‐based cohort study using a prevalent new‐user design and
Wang‐Choi Tang, Pauline Reynier, Antonios Douros, Oriana H. Y. Yu, Robert W. Platt, Kristian B. Filion   +5 more
wiley   +1 more source

Arrhythmic events pertinent with antidepressants: a Bayesian disproportional analysis mining the FDA Adverse Event Reporting System database. [PDF]

Front Psychiatry
Cao S, Huang Z, Yang W, Yang S, Chen X, Xie X.   +5 more
europepmc   +1 more source

Cardiovascular Challenges in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Bruton Tyrosine Kinase (BTK) Inhibitor Therapy

European Journal of Haematology, Volume 116, Issue 2, Page 104-115, February 2026.
ABSTRACT Background/Objectives Bruton tyrosine kinase inhibitors (BTKis) have revolutionized treatment for chronic lymphocytic leukemia (CLL), but cardiovascular (CV) toxicities pose significant challenges. Second‐generation BTKis offer improved target specificity, yet CV risks persist.
Stefano Oliva, Stefano Molica
wiley   +1 more source

Inflammatory cytokines and cardiac arrhythmias: from pathogenesis to potential therapies. [PDF]

Ann Med Surg (Lond)
Obeagu EI.
europepmc   +1 more source

T‐Cell–Redirecting Immunotherapies in Relapsed/Refractory Mantle Cell Lymphoma: Current Evidence, Sequencing, and Future Directions

European Journal of Haematology, Volume 116, Issue 2, Page 129-141, February 2026.
ABSTRACT Relapsed/refractory (R/R) mantle cell lymphoma (MCL) remains a therapeutic challenge, particularly in patients with high‐risk features or prior exposure to Bruton's tyrosine kinase inhibitors (BTKis). The advent of T‐cell–redirecting immunotherapies, including chimeric antigen receptor T‐cell (CAR‐T) therapy and bispecific antibodies (BsAbs ...
Santino Caserta, Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Fortunato Morabito, Massimo Gentile   +10 more
wiley   +1 more source